Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097725 | 0.96 | — | — | |
| SCHEMBL1746 | 0.96 | — | — | |
| SCHEMBL5544690 | 0.96 | MEN1 (0.42) | MEN1KMT2A | |
| Fluoride SCHEMBL73855 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL1025917 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3210291 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL1997314 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL2232066 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22577541 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL319537 | 0.92 | MEN1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247328-B1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20250276000-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2025-09-04 | — | — | US | disclosed |
| US-20230038687-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-02-09 | — | — | US | disclosed |
| CN-114642735-A | Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells | 菲泽尔克斯公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-107530436-B | Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells | 菲泽尔克斯公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11219634-B2 | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | GENEVANT SCIENCES GMBH (CH) | 2022-01-11 | — | — | US | disclosed |
| US-20180221402-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | ROIVANT SCIENCES LTD. (GB) | 2018-08-09 | — | — | US | disclosed |
| EP-3247328-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PhaseRx, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118697-A9 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016118697-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-2424918-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel Corporation (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127055-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2001007013-A9 | THIOAMIDE MOIETY-CONTAINING POLYMER DRUG CONJUGATES | UNIV NEW JERSEY MED (US) | 2002-11-14 | — | — | WO | disclosed |
| US-6468522-B1 | Controlled release of thioamide moiety-containing therapeutic agents | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2002-10-22 | — | — | US | disclosed |
| US-20020122785-A1 | Materials and processes for controlled release of thioamide moiety-containing therapeutic agents by linking to thiol-containing polymers | STEIN STANLEY (US) | 2002-09-05 | — | — | US | disclosed |
| WO-2001007013-A2 | THIOAMIDE MOIETY-CONTAINING POLYMER DRUG CONJUGATES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-0356173-B1 | Fluorescent dyes | SYNTEX INC (US) | 1995-05-10 | — | — | EP | disclosed |
| US-5145774-A | Squarylium detergent dyes, staining, nonleaching, blood typing and antigens | SYNTEX (U.S.A.) INC. (US) | 1992-09-08 | — | — | US | disclosed |
| US-5026905-A | Slow leaching stains for blood typing antibodies-antigens | SYNTEX (U.S.A.) INC. (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0356173-A2 | Fluorescent dyes | SYNTEX (U.S.A.) INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276000-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | MEN1 2379/4885KMT2A 4574/4885 |
| US-11219634-B2 | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | CD63, LIPA, NPC1L1 | MEN1 2379/4885KMT2A 4574/4885 |
| US-20230038687-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | MEN1 2379/4885KMT2A 4574/4885 |
| US-20180221402-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | MEN1 2379/4885KMT2A 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.